EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology

Javier Crespo, Marta Alonso-Peña iD, Carolina Jiménez-González iD, Lorena Cayón-Gonzalez, Paula Iruzubieta iD

Pharmaceuticals · 2026-07-24 · 19 (8) · 1145

DOI: 10.3390/ph19081145 ↗

At a glance

Übersichtsarbeit in Pharmaceuticals, published online on 2026-07-24. Written by Javier Crespo and 4 co-authors. Institution: Cantabria Cohort, Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain. 87 references. The full text is freely available (open access, CC BY 4.0). Funded by: European Commission, Institute of Health Carlos III, Instituto de Salud Carlos III.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Metabolic dysfunction-associated steatotic liver disease (MASLD) has traditionally been conceptualized as a predominantly metabolic disorder driven by obesity and insulin resistance. However, recent advances in human genetics have revealed a more complex picture that encompasses germline susceptibility variants, protective loss-of-function alleles, polygenic risk models, and somatic clonal evolution. Since the discovery of PNPLA3 (patatin-like phospholipase domain-containing 3) I148M, multiple loci—including TM6SF2, MBOAT7, GCKR, HSD17B13, MTARC1, GPAM, and CIDEB—have substantially expanded the mechanistic understanding of disease heterogeneity and hepatocellular vulnerability. Recent studies integrating partitioned polygenic risk scores and unsupervised phenotypic clustering suggest that MASLD may be organized into at least two predominant subtypes: a liver-specific subtype characterized by intrinsic hepatocellular susceptibility, and a cardiometabolic subtype associated with systemic metabolic dysfunction and increased cardiovascular risk. Analyses of cirrhotic liver tissue have, in turn, demonstrated somatic clonal expansion of hepatocytes harboring adaptive metabolic mutations, adding an evolutionary dimension to advanced disease. On this basis, we propose an integrated LS/CM/C framework encompassing liver-specific (LS), cardiometabolic (CM), and clonal (C) components. This model offers a conceptual structure that links germline genetics, metabolic heterogeneity, somatic adaptation, and emerging pharmacogenomic strategies. The recent development of genotype-directed therapies targeting PNPLA3 and HSD17B13, together with the approval of resmetirom and semaglutide, further supports the transition toward biologically stratified hepatology. Although prospective validation remains necessary, the convergence of genetics, clonal biology, and targeted therapeutics suggests that MASLD is moving toward an era of precision medicine.

Subjects

Author keywords

HSD17B13MASHMASLDPNPLA3clonal evolutiongeneticshepatocellular carcinomapharmacogenomicspolygenic risk scoresprecision medicine

Authors and institutions

  • Cantabria Cohort, Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
  • Departmento de Medicina, Universidad de Cantabria, 39011 Santander, Spain.
  • MedicineAI, 28027 Madrid, Spain.
  • Departamento de Anatomía y Biología Celular, Universidad de Cantabria, 39011 Santander, Spain.
  • Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
  • Gastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.

ORCID profiles: Marta Alonso-Peña, Carolina Jiménez-González, Paula Iruzubieta

Funding

  • European Commission
  • Institute of Health Carlos III
  • Instituto de Salud Carlos III
  • European Union-NextGenerationEU programme

Cite

APA

Crespo, J., Alonso-Peña, M., Jiménez-González, C., Cayón-Gonzalez, L., & Iruzubieta, P. (2026). Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology. Pharmaceuticals, 19(8), 1145. https://doi.org/10.3390/ph19081145

Vancouver

Crespo J, Alonso-Peña M, Jiménez-González C, Cayón-Gonzalez L, Iruzubieta P. Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology. Pharmaceuticals. 2026;19(8):1145. doi:10.3390/ph19081145

BibTeX
@article{Crespo2026,
  author = {Crespo, Javier and Alonso-Peña, Marta and Jiménez-González, Carolina and Cayón-Gonzalez, Lorena and Iruzubieta, Paula},
  title = {Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1145},
  doi = {10.3390/ph19081145}
}
Start for free →